Sabrina Kay Appointed to MannKind Board of Directors
MannKind Corporation (NASDAQ: MNKD) announced the appointment of Sabrina Kay, Ed.D., to its Board of Directors, effective December 1, 2020. Dr. Kay will also join the Audit Committee, bringing extensive experience in marketing, finance, and executive leadership. Currently the CEO of Fremont Private Investments, she has successfully managed several companies and is involved in numerous philanthropic initiatives. With Dr. Kay's appointment, MannKind aims to enhance its strategic vision and leadership as it continues to develop its inhaled therapeutic products, including Afrezza.
- Sabrina Kay brings extensive leadership experience and a fresh perspective to the Board.
- Her entrepreneurial background may enhance MannKind's strategic vision and pipeline expansion.
- Concerns about continuity and experience gaps in the Board due to the recent appointment.
WESTLAKE VILLAGE, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Sabrina Kay Ed.D. has been appointed to its Board of Directors, effective December 1, 2020. Dr. Kay will also serve as a member of the Audit Committee of the Board. A serial entrepreneur, tech educator, fashion designer, philanthropist, and public speaker, Dr. Kay brings to MannKind a wealth of experience in marketing, human capital development, finance and executive leadership.
“We are excited to welcome Dr. Kay and her years of invaluable leadership to our Board of Directors,” said Kent Kresa, Chairman of the Board. “Her entrepreneurial vision will be a critical asset for MannKind as the company continues to evolve and the pipeline expands. Dr. Kay has a successful track record in launching and leading a variety of companies, and will add a fresh and diverse perspective as we continue to pursue our mission to give people control of their health and the freedom to live life.”
Currently, Dr. Kay serves as Founder and CEO of Fremont Private Investments, where she has led the operations and exits of several companies including The Art Institute of Hollywood (sold to NASDAQ: EDMC), Premier Business Bank (sold to NASDAQ: FFWM), Fashion Umbrella, Fremont College, and Dale Carnegie of Los Angeles.
In addition to her success in the business world, Dr. Kay is a philanthropist, having served on more than 30 charitable and civic boards. She is chairman of After-School All-Stars Los Angeles, and a board member of the Los Angeles Sports and Entertainment Commission, Petersen Automotive Museum, Portal Schools, the Leadership Council of International Medical Corps Leadership Council, and the Board of Leaders of USC Marshall School. Dr. Kay has also chaired and spoken at numerous tech, education, business, and leadership conferences, and taught entrepreneurship programs at various universities.
Dr. Kay’s achievements have been recognized with numerous awards, including the Education Award from After-School All-Stars and the Humanitarian Award from International Medical Corps. She was named Woman of the Year by the California Legislature, Rising Asian Woman by the World Affairs Council, and was a finalist for Entrepreneur of the Year by Ernst & Young.
Dr. Kay received her joint doctorate degree in Work-based Learning Leadership from the University of Pennsylvania. She holds an MBA from the University of Southern California and a Master of Science degree in education from the University of Pennsylvania.
With the addition of Dr. Kay, there are nine members of the MannKind Board of Directors.
About MannKind Corporation
MannKind Corporation (NASDAQ: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind's filings with the SEC. For a discussion of these and other factors, please refer to MannKind’s annual report on Form 10-K for the year ended December 31, 2019 as well as MannKind’s other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
Company Contact:
818-661-5000
ir@mannkindcorp.com
FAQ
Who is Sabrina Kay and what is her role at MannKind Corporation?
When did Sabrina Kay join MannKind's Board of Directors?
What is the significance of Sabrina Kay's appointment for MannKind Corporation?
What is MannKind Corporation known for?
